Detailed Information on Publication Record
2024
Prostate cancer diagnosed and staged using UV-irradiated urine samples and a paper-based analytical device
BEZDEKOVA, Jaroslava, Mariana PLEVOVÁ, Lukas NEJDL, Mirek MACKA, Michal MASAŘÍK et. al.Basic information
Original name
Prostate cancer diagnosed and staged using UV-irradiated urine samples and a paper-based analytical device
Authors
BEZDEKOVA, Jaroslava (203 Czech Republic), Mariana PLEVOVÁ (703 Slovakia), Lukas NEJDL (203 Czech Republic), Mirek MACKA (203 Czech Republic), Michal MASAŘÍK (203 Czech Republic, belonging to the institution), Dalibor PACIK (203 Czech Republic), Vojtech ADAM (203 Czech Republic) and Marketa VACULOVICOVA (203 Czech Republic, guarantor)
Edition
Sensors and Actuators B: Chemical, LAUSANNE, Elsevier B.V. 2024, 0925-4005
Other information
Language
English
Type of outcome
Článek v odborném periodiku
Field of Study
30204 Oncology
Country of publisher
Switzerland
Confidentiality degree
není předmětem státního či obchodního tajemství
References:
Impact factor
Impact factor: 8.400 in 2022
Organization unit
Faculty of Medicine
UT WoS
001143020700001
Keywords in English
Molecularly imprinted polymers; UV -induced fluorescent clusters; UV -induced fluorescence fingerprinting
Tags
International impact, Reviewed
Změněno: 23/2/2024 12:33, Mgr. Tereza Miškechová
Abstract
V originále
The early detection of prostate cancer (CaP), one of the most common cancers in males, improves treatment efficacy. However, current methods to detect CaP are limited by specificity and sensitivity or require an invasive and unpleasant procedure. Therefore, there is a need for a novel, fast, and noninvasive CaP detection method. This proof-of-concept study aimed to diagnose CaP from urine samples by detecting the UV-induced fluorescent clusters formed in situ that reflect a urine composition specific to CaP patients using fluorescence spectroscopy. The UV-induced clusters formed upon irradiation by UV light with a wavelength of 254 nm were detected at excitation and emission wavelengths of 400 nm and 460 nm. Fifteen patients with CaP were correctly distinguished from 5 controls. The different stages of CaP could be further determined using molecular imprinting technology. Additionally, a paper-based analytical device was developed that enabled the correct identification of stage I cancer patients by fluorescent spectroscopy detection and the naked eye. In conclusion, this novel, easyto-operate, point-of-care assay can enable early diagnosis of CaP with high accuracy and judgement of the disease stage. The simplicity, as well as versatility of the proposed method, will enable its application also to other diseases and disorders.